Advanced Enzyme Technologies Limited Sales Rise 2.08% in June

Advanced Enzyme Technologies Limited reported consolidated net sales of ₹189.79 crore for the June 2026 quarter, a 2.08% increase from a year earlier. The reported sales figure was 6.68% lower than the preceding quarter, indicating a sequential moderation despite year-on-year growth in the company’s top line.

What did Advanced Enzymes report for the June 2026 quarter?

Advanced Enzymes reported consolidated net sales of ₹189.79 crore for the quarter ended June 2026. The available quarterly data shows that sales increased 2.08% on a year-on-year basis, while declining 6.68% from the immediately preceding quarter.

The quarterly update also lists gross profit at ₹41 crore. No corresponding comparative gross-profit figure, net-profit figure, or detailed segment-level break-up for the June 2026 period is included in the available information. Therefore, the disclosed sales trend is the clearest measure of the company’s latest operating performance in this dataset.

The company’s upcoming earnings date is listed as October 31, 2026, under Q2 FY 2026-27. That result is expected to provide a subsequent update on revenue, profitability and other operating metrics after the June-quarter data.

How does the June sales number compare with earlier reported results?

The June 2026 net-sales number should be distinguished from Advanced Enzymes’ previously disclosed September 2025 results, which contained both revenue from operations and total income. For Q2 FY26, the company reported consolidated revenue from operations of ₹184.50 crore, compared with ₹146.10 crore in Q2 FY25, representing 26% year-on-year growth.

For that September 2025 quarter, total income was ₹194.81 crore, nearly unchanged from ₹194.76 crore in the preceding June 2025 quarter. Total income includes other income and is therefore not directly comparable with net sales or revenue from operations without adjustment.

The earlier quarterly-results table showed September 2025 net sales turnover of ₹184.53 crore, versus ₹185.91 crore in June 2025. The newly listed June 2026 net sales of ₹189.79 crore are higher than that September 2025 sales figure, but the available data does not provide a full comparable series for all intervening quarters.

What were Advanced Enzymes’ profit trends in the September 2025 quarter?

Advanced Enzymes reported a stronger profit performance in Q2 FY26, the quarter ended September 2025. Profit before tax rose to ₹59.54 crore from ₹42.21 crore in Q2 FY25, an increase of 41.1%, while profit after tax rose 34% to ₹44.74 crore from ₹33.39 crore.

The company’s EBITDA for the period was ₹60.10 crore, up 42% year-on-year from ₹42.40 crore. EBITDA margin stood at 33%, while profit-after-tax margin was 24%, according to the company’s results communication.

On a sequential basis, profit after tax increased from ₹40.44 crore in the June 2025 quarter to ₹44.74 crore in the September 2025 quarter. Profit before tax rose from ₹54.90 crore to ₹59.54 crore over the same comparison. These results show that profitability improved in that earlier period even as reported total income was broadly stable quarter on quarter.

Which markets contributed to the earlier revenue growth?

Advanced Enzymes identified Human Healthcare, Bioprocessing and Specialized Manufacturing as contributors to its revenue growth in the September 2025 quarter. Domestic sales rose 26% year-on-year to ₹88.70 crore, compared with ₹70.30 crore in Q2 FY25.

Geographically, sales in Europe increased to ₹11.60 crore from ₹5.40 crore, while Asia sales rose to ₹25.60 crore from ₹10.10 crore. Americas sales were ₹55.40 crore, compared with ₹57.10 crore a year earlier. Sales in the rest of the world were broadly unchanged at ₹3.20 crore.

The company also noted challenges in the US market related to tariff issues during its discussion of the September 2025 results. The available June 2026 update does not provide a country-wise or business-segment revenue split, so it does not establish whether these regional patterns continued into the latest reported quarter.

Why do the June sales figures matter for investors?

The June 2026 sales data indicates that Advanced Enzymes maintained year-on-year growth, although the 2.08% increase was substantially lower than the 26% growth reported for revenue from operations in the September 2025 quarter. The 6.68% sequential decline also makes the next earnings release important for assessing the direction of demand and operating performance.

For investors, sales alone do not show the full financial outcome because costs, margins, other income and tax expenses can materially affect profit. The reported gross profit of ₹41 crore provides one indicator, but the available June-quarter information does not disclose EBITDA, profit before tax, profit after tax or margins.

The comparison also underlines the need to use like-for-like measures. Net sales, revenue from operations and total income are separate reporting measures. Advanced Enzymes’ October 31, 2026 earnings update will be relevant for a clearer assessment of how the company’s sales and profitability have moved after the June quarter.

Conclusion

Advanced Enzyme Technologies Limited recorded consolidated June 2026 net sales of ₹189.79 crore, delivering modest year-on-year growth of 2.08% but a 6.68% decline from the prior quarter. The figure follows a stronger profitability and revenue performance reported in the September 2025 quarter, when the company posted 26% growth in revenue from operations and 34% growth in profit after tax.

The next item to watch is the company’s listed October 31, 2026 earnings date for Q2 FY 2026-27. That disclosure may clarify whether sequential sales pressure persisted, how gross profit translated into operating and net profit, and whether regional and segment trends changed after the June quarter.